No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LEGN Legend Biotech
- 50.120
- -1.590-3.07%
Close Apr 16 16:00 ET
- 50.120
- 0.0000.00%
Post 16:36 ET
9.12BMarket Cap-17047P/E (TTM)
50.580High48.980Low2.70MVolume50.000Open51.710Pre Close134.45MTurnover3.40%Turnover RatioLossP/E (Static)181.91MShares77.32052wk High7.29P/B3.98BFloat Cap48.98052wk Low--Dividend TTM79.38MShs Float77.320Historical High--Div YieldTTM3.09%Amplitude23.410Historical Low49.873Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
HC Wainwright & Co. : Legendary Creatures (LEGN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $87.00.
HC Wainwright & Co. : Legendary Creatures (LEGN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $87.00.
HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $87 price target.
Legend Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 74.7% HC Wainwright & Co. → $87 Reiterates Buy → Buy 04/03/2024 64.66% Cantor Fitzgerald → $82
Buy Rating Affirmed for Legend Biotech Amidst Growth Prospects and CARVYKTI's Market Expansion
Legend Biotech Earlier Announced CARVYKTI Generated Approximately $157M In Net Trade Sales During The Quarter Ended Mar. 31.
Legend Biotech Earlier Announced CARVYKTI Generated Approximately $157M In Net Trade Sales During The Quarter Ended Mar. 31.
Legend Biotech Reports Preliminary Sales Surge
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg